2020-08-14T13:05:46-05:00 2019-09-30 ERNST & YOUNG US LLP 18101 VON KARMAN AVE SUITE 1700 IRVINE CA 92612 990 2018-10-01 953432210 BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE % JENNIFER PARKHURST BECK 6262564673 1450 EAST DUARTE ROAD DUARTE CA 91010 JENNIFER PARKHURST CFO 2020-08-05 true Kara Adams P00023315 9497942300 76.103.183.71 33577420202275000028 2020-08-14 P 082CA6B79275EA4790B1F414F298E8EA5742CACC C14809353AC8B922CDA71DEA69DCA1FF1BA1B89C 2018 2020-09-23 17:36:50Z ROBERT W STONE 1500 EAST DUARTE ROAD DUARTE CA 91010 1103939965 false X WWW.CITYOFHOPE.ORG X 1979 CA TO DISCOVER AND TRANSLATE INNOVATIVE LABORATORY FINDINGS INTO NEW CLINICAL TREATMENTS BY USING PRACTICAL APPLICATIONS OF CHEMISTRY, PHYSICS, AND BIOLOGY. 8 6 1334 0 1511610 0 451252545 447275376 21528701 25851875 56284277 89982154 56334527 5288621 585400050 568398026 0 0 0 0 155658428 172298453 0 0 4218288 278277838 253797389 433936266 426095842 151463784 142302184 1472757241 1556201710 164197421 219875514 1308559820 1336326196 X THE SPECIFIC AND PRIMARY PURPOSE IS TO DIRECTLY ENGAGE IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH. SEE SCHEDULE O. false false 357792304 0 25851875 BIOMEDICAL RESEARCH AND DISEASE INVESTIGATIONS, INCLUDING DNA SYNTHESIS AND CELL ANALYSIS. BECKMAN RESEARCH INSTITUTE HAS PIONEERED SCIENTIFIC BREAKTHROUGHS RESULTING IN TREATMENTS THAT HAVE IMPROVED THE LIVES OF PATIENTS WORLDWIDE. NUMEROUS LIFE-SAVING DRUGS USE PATENTED TECHNOLOGY DEVELOPED AT BECKMAN RESEARCH INSTITUTE; THESE DRUGS INCLUDE SYNTHETIC HUMAN INSULIN (HUMULIN) FOR DIABETES, THE WIDELY USED CANCER DRUGS HERCEPTIN, RITUXAN AND AVASTIN, AND HUMIRA FOR ARTHRITIS. SEE SCHEDULE O. 357792304 true true false false false false false false false true true true false false true true false true false false true false false false false false false false false true true false false false false false true false false true false false false false false false true true true false false true 455 0 true 1334 true true true true BD CJ false false false false false false false false true false X 8 6 false false false false true true true true true false false false true true true true true true true false CA X JENNIFER PARKHURST 6262564673 1500 EAST DUARTE ROAD DUARTE CA 91010 X ART NEMIROFF BOARD MEMBER 2.0 0.0 X 0 0 0 BENHAM BADIE MD BOARD MEMBER 2.0 0.0 X 0 0 0 ERNIE SO BOARD MEMBER 2.0 2.0 X 0 0 0 GARY E FREEDMAN BOARD MEMBER 2.0 0.0 X 0 0 0 JODY HOROWITZ MARSH BOARD MEMBER 2.0 5.0 X 0 0 0 JOHN J ROSSI BOARD MEMBER/PROFESSOR 60.0 0.0 X 330484 0 65412 LINDA HELEN MALKAS BOARD MEMBER/PROFESSOR 60.0 0.0 X 400624 0 54919 STEVEN FINK BOARD MEMBER/CHAIR 2.0 3.0 X X 0 0 0 GREGORY SCHETINA GENERAL COUNSEL/SECRETARY 15.0 45.0 X 251396 754186 187797 JEFFREY WALKER COO/ASSISTANT SECRETARY 15.0 45.0 X 197499 592495 58645 JENNIFER PARKHURST CFO/TREASURER 15.0 45.0 X 307559 922674 80629 ROBERT W STONE PRESIDENT/CEO 15.0 45.0 X 725658 2176971 463619 ASHLEY BAKER LEE SVP RSCH OPS 24.0 36.0 X 285587 428379 59462 DAVID A HORNE VICE PROVOST 51.0 9.0 X 592858 104623 58532 JONATHAN REUTER VP FACILITIES & CONSTRUCTION 24.0 36.0 X 177851 266775 43609 MARK HULSE CHIEF DIGITAL OFFICER 15.0 45.0 X 184267 552800 76038 STEVEN TERRY ROSEN MD PROVOST & CHIEF SCIENTIFIC OFF 34.0 25.8 X 1067645 805416 233383 DEBRA F FIELDS EVP CHIEF TRANSFORMATION OFF. 15.0 45.0 X 291432 874294 203665 HARLAN LEVINE MD PRES STRATEGY & BUS. VENTURES 18.0 42.0 X 565932 1320508 253702 KRISTIN BERTELL EVP DEVEL & EXT AFFAIRS 3.0 57.0 X 58941 1119887 182598 LARRY W KWAK MD ASSOCIATE DIRECTOR 60.0 0.0 X 1189300 0 55430 MICHAEL A CALIGIURI MD PRESIDENT - MEDICAL CENTER 6.0 54.0 X 145234 1307111 105940 CORNELIS VAN DEN BERG FORMER OFFICER 15.0 45.0 X 195276 585827 32318 MICHAEL A FRIEDMAN MD FORMER OFFICER 6.0 54.0 X 19187 172683 38572 WILLIAM SARGEANT FORMER OFFICER 0.0 0.0 X 138487 415461 48718 7125217 12400090 2302988 255 true true false DPR CONSTRUCTION 88 West Colorado Blvd Suite 301 Pasadena CA 91105 Construction SVCS 5823845 LAYTON CONSTRUCTION CO INC 9090 S Sandy Pkwy Sandy UT 84070 Construction SVCS 5089098 MINTZ LEVIN COHN FERRIS GLOVSKY P 2029 century Park East Suite 1370 Los Angeles CA 90067 Legal Services 2155466 LCS CONSTRUCTORS INC 15205 Alton Pkwy Irvine CA 92618 Construction SVCS 1605880 JONES DAY 555 South Flower St 50 Floor Los Angeles CA 90071 Legal Services 1188733 21 0 349931002 83700075 13644299 0 447275376 OTHER RESEARCH ACTIVITIES 541990 25170816 25170816 0 0 Specialized Lab Revenue 541900 490197 490197 0 0 RENTAL INCOME - PROGRAM SERVICE 721310 117754 117754 0 0 GRADUATE EDUCATION PROGRAM 611310 38488 38488 0 0 INTERNATIONAL STUDIES OFFICE 923110 29120 29120 0 0 5500 5500 0 0 25851875 18667428 18667428 0 3777011 3777011 0 0 0 606856665 535541939 71314726 71314726 71314726 0 0 0 0 0 0 0 0 0 INVESTMENT INCOME FROM K-1'S 525990 1511610 0 1511610 0 1511610 568398026 25851875 1511610 93759165 0 0 0 0 0 0 0 0 5226774 1833242 3251347 142185 657438 28956 628482 0 135136222 112233867 19880433 3021922 8382268 7183652 1006042 192574 15048640 12408603 2297918 342119 7847111 6239688 1434909 172514 0 0 0 0 5705453 125293 5580160 0 330861 330861 0 0 0 0 0 0 0 0 0 0 0 33233515 23433354 9800161 0 2703277 5508 2697769 0 41155434 38715906 2381215 58313 6242162 786245 5452149 3768 0 0 0 0 8475931 7606644 769741 99546 2402604 1962048 440556 0 0 0 0 0 787794 403066 384728 0 4926526 4446535 479991 0 0 0 0 0 25448447 18866914 6411921 169612 462245 426473 23981 11791 Royalty Revenue Sharing 118425030 118425030 0 0 Dues and Subscriptions 2348941 1985270 363671 0 BAD DEBT 533374 533374 0 0 UBI TAX EXPENSE 118152 0 118152 0 497643 142636 351063 3944 426095842 357792304 64085250 4218288 0 10744967 23933798 1361870 1381787 15683883 24387185 0 0 408956 395242 0 0 7382129 7122038 0 0 402293 226077 546194953 209318958 334190994 336875995 456251217 478588806 635597845 634656278 0 0 0 0 10733087 48634504 1472757241 1556201710 30697855 55751945 0 0 17231897 20691952 52322661 51875194 0 0 0 0 50000000 50000000 0 0 13945008 41556423 164197421 219875514 X 1285464248 1313055819 9202180 9362248 13893392 13908129 1308559820 1336326196 1472757241 1556201710 X 142302184 -69835968 0 0 0 -44699840 X false true X true true true X CITY OF HOPE NATIONAL MEDICAL CENTER DUARTE CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 750855062 14850 15019931 404885 765484958 693069392 30113 58203028 447471 750855062 612842871 30000 81045502 0 848981 0 693069392 562143821 30367 51317174 0 648491 0 612842871 576279312 40694 -13645494 0 530691 0 562143821 0.96960 0.01820 0.01220 false false 2592400 2113428 4705828 363828609 116222198 247606411 8572 8572 166360328 93088188 73272140 11291616 11291616 336875995 Alternative Investments 634656278 F 634656278 0 DUE TO AFFILIATES 28406380 INTEREST RATE SWAP LIABILITY 9760731 BOND ISSUANCE PREMIUM 1725885 WORKERS COMPENSATION LIABILITY 1663427 41556423 X SCHEDULE D, PART V, LINE 4 ENDOWMENT FUNDS: BECKMAN RESEARCH INSTITUTE HAS BOARD DESIGNATED ASSETS OR QUASI-ENDOWMENT FUNDS AND OTHER PERMANENT ENDOWMENT FUNDS THAT ARE AVAILABLE TO FUND FUTURE RESEARCH, CAPITAL EXPENDITURES AND OTHER EXPANSION NEEDS AS DETERMINED BY THE MANAGEMENT AND THE BOARD OF DIRECTORS. SCHEDULE D, PART X, LINE 2 FASB ASC 740 DISCLOSURE: THE FOLLOWING PARAGRAPH IS FROM THE CONSOLIDATED CITY OF HOPE AUDITED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2019 (WHICH INCLUDES CITY OF HOPE, CITY OF HOPE AUXILIARIES, CITY OF HOPE NATIONAL MEDICAL CENTER, CITY OF HOPE MEDICAL FOUNDATION, THE BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, AND SOUTHERN CALIFORNIA RADIATION ONCOLOGY, LLC, AND ACCESS CITY OF HOPE, LLC): FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) ACCOUNTING STANDARDS CODIFICATION (ASC) TOPIC ASC 740, INCOME TAXES, CLARIFIES THE ACCOUNTING FOR INCOME TAXES BY PRESCRIBING A MINIMUM RECOGNITION THRESHOLD THAT A TAX POSITION IS REQUIRED TO MEET BEFORE BEING RECOGNIZED IN THE FINANCIAL STATEMENTS. ASC 740 ALSO PROVIDES GUIDANCE ON DE-RECOGNITION, MEASUREMENT, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE AND TRANSITION. THE GUIDANCE CONTAINED IN ASC 740 IS APPLICABLE TO PASS-THROUGH ENTITIES AND TAX-EXEMPT ORGANIZATIONS. CITY OF HOPE HAS NO SIGNIFICANT UNCERTAIN TAX POSITIONS OR TAX LIABILITY FOR TAX BENEFITS, INTEREST OR PENALTIES ACCRUED AT SEPTEMBER 30, 2019 AND 2018. Central America and the Caribbean 0 3 Program Services Research Symposiums 6164 East Asia and the Pacific 0 46 Program Services Research Symposiums 152568 Europe (Including Iceland and Greenland) 0 46 Program Services Research Symposiums 224531 Middle East and North Africa 0 6 Program Services Research Symposiums 30957 North America 0 36 Program Services Research Symposiums 63999 South America 0 1 Program Services Research Symposiums 1337 Sub-Saharan Africa 0 1 Program Services Research Symposiums 1230 Central America and the Caribbean 0 0 Investments 117151249 0 116 0 139 117632035 117632035 true false true true true false SCHEDULE F, PART I, LINE 3 ACTIVITIES PER REGION: INVESTMENT ACTIVITIES OF THE BECKMAN RESEARCH INSTITUTE INCLUDE INVESTMENTS IN MULTIPLE VEHICLES THAT PROVIDE INVESTMENT INCOME AND RETURNS TO THE INSTITUTION TO FURTHER ITS MISSION AND PROGRAMS. AS A RESULT, THERE ARE INVESTMENTS HELD IN OFFSHORE HEDGE FUNDS, MAINLY REGISTERED AS CAYMAN EXEMPTED CORPORATIONS. THESE INVESTMENTS HELP MITIGATE RISK IN THE PORTFOLIO AND REPRESENT APPROXIMATELY 10.29% OF BECKMAN RESEARCH INSTITUTE'S OVERALL CASH AND INVESTMENT PORTFOLIO. THE BECKMAN RESEARCH INSTITUTE HAS HOLDINGS THAT INCLUDE EQUITY COMINGLED FUNDS THAT INVEST PRIMARILY IN MARKETABLE EQUITY SECURITIES. THESE FUNDS ARE SUBJECT TO CERTAIN NOTICE REQUIREMENTS, BUT CAN BE LIQUIDATED AT LEAST MONTHLY. ALTERNATIVE INVESTMENTS ALSO INCLUDE HEDGE FUNDS AND LIMITED PARTNERSHIP FUNDS INVESTED IN REAL ESTATE AND NATURAL RESOURCES, MASTER LIMITED PARTNERSHIPS, PRIVATE EQUITY AND PRIVATE REAL ASSET FUNDS. THESE INVESTMENTS HAVE BEEN INCLUDED IN FORM 990, PART X, LINE 12. RESEARCH SYMPOSIA CONSIST OF SCIENTIFIC MEETINGS THAT BECKMAN RESEARCH INSTITUTE PRINCIPAL INVESTIGATORS AND OTHER RESEARCH STAFF ATTEND FOR EDUCATIONAL, RESEARCH AND SCIENTIFIC PURPOSES AND TO PRESENT AND SHARE RESEARCH OBJECTIVES AND RESULTS. RESEARCH ACTIVITIES SPAN GLOBALLY AND RESEARCH SYMPOSIA ARE OFTEN CONDUCTED IN THE VARIOUS REGIONS IDENTIFIED IN SCHEDULE F. CITY OF HOPE SUPPORTS ATTENDANCE OF OUR RESEARCH STAFF AT THESE SYMPOSIA. EMPLOYEE TRAVELERS MAY MAKE MULTIPLE TRIPS TO THE SAME REGION OR TO MULTIPLE REGIONS DURING A FISCAL YEAR. IN THE CASE WHERE THE SAME EMPLOYEE TRAVELER MADE MORE THAN ONE TRIP TO THE SAME REGION, THEY ARE ONLY COUNTED ONE TIME AS A TRAVELER TO THAT REGION. IF THE SAME EMPLOYEE TRAVELER TRAVELS TO MORE THAN ONE REGION, THAT INDIVIDUAL IS COUNTED ONLY ONCE IN EACH REGION VISITED. THE TOTAL TRAVELERS ON LINE 3A, HOWEVER, ONLY COUNTS THE SAME TRAVELER ONCE IN THE GRAND TOTAL. AS A RESULT THE TOTAL TRAVELERS PER REGION WILL NOT ADD UP TO THE TOTAL ON LINE 3A. WE HAD 18 INSTANCES IN WHICH THE SAME TRAVELER TRAVELED TO MULTIPLE REGIONS DURING THE FISCAL YEAR ENDING SEPTEMBER 30, 2019. THE BECKMAN RESEARCH INSTITUTE DOES NOT HAVE ANY PHYSICAL PRESENCE OR EMPLOYEES OUTSIDE OF THE UNITED STATES. THE BECKMAN RESEARCH INSTITUTE'S REPUTATION AS A WORLD CLASS RESEARCH AND TREATMENT FACILITY IS INTERNATIONALLY RECOGNIZED. AS A RESULT OF THIS RECOGNITION, THE BECKMAN RESEARCH INSTITUTE RECEIVES DONATIONS AND GRANTS FROM PERSONS AND CORPORATIONS OUTSIDE OF THE UNITED STATES. SCHEDULE F, PART I, COLUMN F EXPENDITURES ARE DETERMINED USING THE ACCRUAL METHOD OF ACCOUNTING. X X X X X X X false true false false false false false true false JOHN J ROSSI BOARD MEMBER/PROFESSOR 312056 0 15766 0 2662 0 41250 0 24162 0 395896 0 0 0 LINDA HELEN MALKAS BOARD MEMBER/PROFESSOR 397948 0 0 0 2676 0 41250 0 13669 0 455543 0 0 0 GREGORY SCHETINA GENERAL COUNSEL/SECRETARY 129638 388913 110767 332302 10991 32971 35347 106042 11602 34806 298345 895034 27923 83769 JEFFREY WALKER COO/ASSISTANT SECRETARY 122562 367687 63654 190961 11283 33847 8000 24000 6661 19984 212160 636479 0 0 JENNIFER PARKHURST CFO/TREASURER 174449 523345 102616 307846 30494 91483 13500 40500 6657 19972 327716 983146 0 0 ROBERT W STONE PRESIDENT/CEO 333194 999580 365727 1097182 26737 80209 106841 320523 9064 27191 841563 2524685 80584 241750 ASHLEY BAKER LEE SVP RSCH OPS 179208 268812 93207 139810 13172 19757 8946 13418 14839 22259 309372 464056 0 0 DAVID A HORNE VICE PROVOST 405340 71531 147197 25976 40321 7116 19009 3355 30743 5425 642610 113403 0 0 JONATHAN REUTER VP FACILITIES & CONSTRUCTION 131681 197521 36985 55477 9185 13777 4280 6419 13164 19746 195295 292940 0 0 MARK HULSE CHIEF DIGITAL OFFICER 126125 378374 41192 123577 16950 50849 10625 31875 8385 25153 203277 609828 0 0 STEVEN TERRY ROSEN MD PROVOST & CHIEF SCIENTIFIC OFF 488604 368596 515841 389143 63200 47677 115742 87315 17286 13040 1200673 905771 102600 77400 DEBRA F FIELDS EVP CHIEF TRANSFORMATION OFF. 149395 448186 131206 393616 10831 32492 40016 120048 10900 32701 342348 1027043 29531 88594 HARLAN LEVINE MD PRES STRATEGY & BUS. VENTURES 269321 628416 269929 629833 26682 62259 65684 153263 10427 24328 642043 1498099 52515 122535 KRISTIN BERTELL EVP DEVEL & EXT AFFAIRS 26566 504755 24738 470021 7637 145111 7172 136260 1958 37208 68071 1293355 9159 174022 LARRY W KWAK MD ASSOCIATE DIRECTOR 738594 0 194835 0 255871 0 8432 0 46998 0 1244730 0 152731 0 MICHAEL A CALIGIURI MD PRESIDENT - MEDICAL CENTER 83568 752115 44615 401539 17051 153457 6667 60000 3927 35346 155828 1402457 0 0 CORNELIS VAN DEN BERG FORMER OFFICER 110500 331499 48496 145488 36280 108840 2108 6324 5972 17914 203356 610065 17211 51631 MICHAEL A FRIEDMAN MD FORMER OFFICER 18636 167721 0 0 551 4962 1449 13038 2409 21676 23045 207397 0 0 WILLIAM SARGEANT FORMER OFFICER 97110 291329 0 0 41377 124132 5591 16773 6589 19765 150667 451999 0 0 SCHEDULE J, PART I, LINE 1A THE ORGANIZATION PERMITS FIRST CLASS TRAVEL FOR CERTAIN OFFICERS, DIRECTORS, AND KEY EXECUTIVES IN LIMITED CIRCUMSTANCES WHEN SPECIFIED TRAVEL CRITERIA ARE MET. SCHEDULE J, PART I, LINE 4B THE BECKMAN RESEARCH INSTITUTE ALSO HAS A NON-QUALIFIED SECTION 457(F) EXECUTIVE SUPPLEMENTAL ACCUMULATION PLAN THAT IS DESIGNED AND MAINTAINED TO PROVIDE A SELECT GROUP OF MANAGEMENT OR HIGHLY COMPENSATED EMPLOYEES WITH DEFERRED COMPENSATION. THE PLAN VESTS AFTER THREE (3) FISCAL YEARS OF SERVICE AND THE VESTED TOTALS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN B (III). PRIOR TO VESTING, THE ANNUAL AMOUNTS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN C. PURSUANT TO THE PLAN DOCUMENT, VESTED PARTICIPANTS ARE ENTITLED TO WITHDRAW FROM THEIR VESTED ACCOUNT AN AMOUNT EQUAL TO THE FEDERAL, STATE, LOCAL AND FICA TAXES THEY OWE. THESE AMOUNTS ARE REMITTED TO THE APPROPRIATE TAXING AUTHORITIES ON BEHALF OF THE PARTICIPANTS. DURING CALENDAR YEAR 2018 THE FOLLOWING INDIVIDUALS WITHDREW THE REFERENCED AMOUNTS TO COVER SUCH TAXES: KRISTIN BERTELL $50,101 CORNELIS VAN DEN BERG $46,611 STEVEN TERRY ROSEN, MD $38,212 ROBERT W. STONE $30,601 DEBRA F. FIELDS $11,292 GREGORY SCHETINA $9,682 DAVID A. HORNE $8,415 ASHLEY BAKER LEE $5,987 MICHAEL A. FRIEDMAN, MD $2,164 THESE AMOUNTS HAVE BEEN INCLUDED IN THE PARTICIPANTS' INCOME ON SCHEDULE J, PART II, COLUMN B(III). WILLIAM SARGEANT ENDED EMPLOYMENT WITH THE CITY OF HOPE NATIONAL MEDICAL CENTER DURING THE CALENDAR YEAR ENDING DECEMBER 31, 2018 AND RECEIVED DISTRIBUTIONS FROM THE PLAN TOTALING $243,977. THIS AMOUNT HAS BEEN REPORTED AS TAXABLE COMPENSATION IN EITHER THE CURRENT YEAR OR IN A PRIOR YEAR 990 IN SCHEDULE J, PART II, COLUMN B(III). SCHEDULE J, PART I, LINE 7 THE BECKMAN RESEARCH INSTITUTE EXECUTIVES AND SOME KEY EMPLOYEES ARE ELIGIBLE TO RECEIVE INCENTIVE COMPENSATION UNDER AN ANNUAL INCENTIVE PLAN (AIP) TIED TO THREE (3) KEY INDICATORS AND TWO OR MORE INDIVIDUAL OBJECTIVES. THE KEY INDICATORS REFLECT KEY AREAS OF STRATEGIC FOCUS AND THE EXEMPT HEALTHCARE MISSION OF THE CITY OF HOPE AND AFFILIATES AND ARE BOTH FINANCIAL AND NON-FINANCIAL. THE POTENTIAL INCENTIVE COMPENSATION IS BASED ON A WEIGHTED AVERAGE AMONG ALL INDICATORS AND IS PAID AS A PERCENTAGE OF EACH INDIVIDUAL PARTICIPANT'S BASE COMPENSATION. THE KEY INDICATORS ARE WEIGHTED AT 50% AND THE INDIVIDUAL OBJECTIVES ARE WEIGHTED AT 50%. THE AIP IS UNDER THE CONTROL OF AND ADMINISTERED BY THE INDEPENDENT DIRECTORS SERVING ON THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE. TO BE ELIGIBLE, THE PARTICIPANTS IN THE AIP MUST BE EMPLOYED BY THE BECKMAN RESEARCH INSTITUTE AT THE TIME OF THE INCENTIVE PLAN PAYMENT, AND BE MEETING OR EXCEEDING PERFORMANCE EXPECTATIONS. CITY OF HOPE MAY IN ITS DISCRETION CANCEL ALL OR A PORTION OF ANY INCENTIVE PLAN PAYMENT OR AWARD TO ANY PARTICIPANT, WHETHER BEFORE OR FOLLOWING PAYMENT OF SUCH AWARD, SUBJECT TO COMPLIANCE WITH APPLICABLE LAW, UNDER THESE CIRCUMSTANCES (CANCELLATION POLICY): A) AN INCENTIVE PLAN PAYMENT OR AWARD IS MADE FOR A FISCAL PERIOD AND CITY OF HOPE SUBSEQUENTLY RESTATES OR OTHERWISE ADJUSTS THE ANNUAL PERFORMANCE MEASUREMENT CALCULATION IN A MANNER THAT WOULD REDUCE THE SIZE OF THE AWARD OR PAYMENT, OR; B) AN INCENTIVE PLAN PAYMENT OR AWARD IS MADE FOR FISCAL PERIOD AND CITY OF HOPE SUBSEQUENTLY DETERMINES THAT ONE OR MORE OF THE ANNUAL PERFORMANCE MEASUREMENT CALCULATIONS ON WHICH THE AWARD IS BASED OR IS PAID ARE MATERIALLY INACCURATE. DURING CALENDAR YEAR 2018 CITY OF HOPE PAID THE INCENTIVE COMPENSATION EARNED FOR FISCAL YEAR 2018 AND THESE AMOUNTS HAVE BEEN REPORTED IN SCHEDULE J, PART II, COLUMN B(II). THE BECKMAN RESEARCH INSTITUTE ALSO HAS AN EXECUTIVE LONG TERM INCENTIVE PLAN (LTI) FOR CERTAIN EXECUTIVES THAT IS DESIGNED TO DRIVE LONG-TERM ORGANIZATIONAL PERFORMANCE AND TRANSFORMATION BY ALIGNING EXECUTIVES WITH THE MULTI-YEAR STRATEGIC PLAN AND INCENTIVIZING THEM FOR ACHIEVING KEY ORGANIZATIONAL AND STRATEGIC OBJECTIVES AND GOALS. WITH THREE-YEAR VESTING PERIODS, THE LTI ALSO PROVIDES A MEANS FOR RETAINING KEY EXECUTIVE TALENT. THE PERFORMANCE PERIOD OF THE PLAN (CYCLE 4) RUNS FROM OCTOBER 1, 2015 THROUGH SEPTEMBER 30, 2018, WITH A NEW THREE YEAR PERFORMANCE PERIOD BEGINNING EACH OCTOBER 1 THEREAFTER (E.G., CYCLE 5 RUNS FROM OCTOBER 1, 2016 THROUGH SEPTEMBER 30, 2019). TO BE ELIGIBLE TO PARTICIPATE IN ANY PAYOUT UNDER THE LTI, PARTICIPANTS MUST BE ACTIVELY EMPLOYED BY THE BECKMAN RESEARCH INSTITUTE AT THE TIME OF THE INCENTIVE PLAN PAYMENT, AND BE MEETING OR EXCEEDING PERFORMANCE EXPECTATIONS. WHILE THE LTI DOES MEET THE REQUIREMENTS FOR A SUBSTANTIAL RISK OF FORFEITURE, AS OF THE CALENDAR YEAR ENDING DECEMBER 31, 2018, THE POTENTIAL LTI AMOUNTS HAVE BEEN ESTIMATED AND ACCRUED DURING THE CURRENT TAX YEAR AND ARE REPORTED AS DEFERRED COMPENSATION TO THE PLAN PARTICIPANTS IN SCHEDULE J, PART II, COLUMN C. THE LTI IS SUBJECT TO THE SAME CANCELLATION POLICY AS THE AIP DESCRIBED ABOVE. PARTICIPANTS WHO MET THE ELIGIBILITY CRITERIA RECEIVED PAYOUT OF PLAN CYCLE 4 LTI INCENTIVES (OCTOBER 1, 2015 THROUGH SEPTEMBER 30, 2018) IN DECEMBER 2018. THESE AMOUNTS HAVE BEEN REFLECTED IN SCHEDULE J PART II, COLUMN B(II). SCHEDULE J, PART II JOHN J. ROSSI, PHD, AND LINDA MALKAS, PHD, ARE MEMBERS OF THE BOARD OF DIRECTORS OF THE BECKMAN RESEARCH INSTITUTE AND ARE ALSO EMPLOYEES OF AND COMPENSATED BY THE BECKMAN RESEARCH INSTITUTE. DR. ROSSI IS A PROFESSOR AND DIRECTOR OF MOLECULAR MEDICINE AND WAS THE DEAN OF THE CITY OF HOPE'S IRELL AND MANELLA GRADUATE SCHOOL OF BIOLOGICAL SCIENCES. DR. MALKAS IS A PROFESSOR AND DEPUTY DIRECTOR FOR BASIC RESEARCH FOR THE CANCER CENTER. NEITHER DR. ROSSI NOR DR. MALKAS ARE COMPENSATED FOR THEIR SERVICES AS A MEMBER OF THE BECKMAN RESEARCH INSTITUTE'S BOARD OF DIRECTORS. EMPLOYEE COMPENSATION FOR BOTH OF THESE INDIVIDUALS IS LISTED ON SCHEDULE J, PART II AND FORM 990, PART VII, SECTION A. A CALIF HLTH FACLTY FIN AUTH (SEE PART VI) 521643828 13033LN37 2012-11-14 57928340 REFUNDING ISSUE/CAPITAL PROJECTS false false false B CALIF HLTH FACLTY FIN AUTH (SEE PART VI) 521643828 2017-02-10 32680000 REFUNDING ISSUE false false false A 32500000 0 57928742 0 0 0 534551 0 0 9853233 47540958 0 2014 true false true true B 0 0 32680000 0 0 0 180000 0 0 0 32500000 0 2012 true false true true A false true true true true true 0.01600 0.01600 false false false true B false true true true true true 0.02100 0.02100 false false false true A false false false true true true WELLS FARGO 30. false false false 0 false true B false false true false true false 0 false 0 false true A true B true SCHEDULE K, PART I, LINE A, COLUMN (E) AN ELECTION WAS MADE UNDER 1.150-1(C)(3) TO TREAT THE BOND ISSUE AS TWO SEPARATE ISSUES AND WAS REPORTED ON TWO SEPARATE FORMS 8038. ONE WAS FOR REFUNDING THE CITY OF HOPE NATIONAL MEDICAL CENTER'S CITY OF DUARTE CERTIFICATES OF PARTICIPATION SERIES 1999A AND THE OTHER WAS FOR REFUNDING (1) THE CITY OF HOPE NATIONAL MEDICAL CENTER PROJECT SERIES 2006A ,B, C ISSUES AND (2) THE BECKMAN RESEARCH INSTITUTE'S 2007 CALIFORNIA ENTERPRISE DEVELOPMENT AUTHORITY ISSUE. THIS SECOND FORM 8038 REPORTED AN ISSUE PRICE OF $198,734,018. FOR PURPOSES OF SCHEDULE K REPORTING, THE BECKMAN RESEARCH INSTITUTE IS REPORTING AN ALLOCABLE AMOUNT OF THE ISSUE PRICE AND EXPENDITURES. BECKMAN RESEARCH INSTITUTE IS REPORTING AN ISSUE PRICE OF $57,928,340, WHILE THE CITY OF HOPE NATIONAL MEDICAL CENTER IS REPORTING AN ISSUE PRICE OF $140,805,678. THE DIFFERENCE BETWEEN THE ISSUE PRICE OF $57,928,340 AND THE TOTAL PROCEEDS OF THE ISSUE OF $57,928,742 IS DUE TO INVESTMENT INCOME. SCHEDULE K, PART I, LINE B, COLUMN (E) THE 02/10/2017 ISSUE WAS ORIGINALLY REPORTED ON A SINGLE FORM 8038 WITH AN ISSUE PRICE OF $65,360,000. FOR PURPOSES OF THE SCHEDULE K REPORTING, THE BECKMAN RESEARCH INSTITUTE IS REPORTING AN ALLOCABLE AMOUNT OF THE ISSUE PRICE AND EXPENDITURES. THE BECKMAN RESEARCH INSTITUTE IS REPORTING AN ALLOCABLE ISSUE PRICE OF $32,680,000 WHILE THE MEDICAL CENTER IS REPORTING THE REMAINDER ON ITS FORM 990 SCHEDULE K. SCHEDULE K, PART I, LINE A COLUMN (F) THE 2012 ISSUE REFUNDED BECKMAN RESEARCH INSTITUTE'S TAX EXEMPT PRIVATE PLACEMENT ISSUED ON JULY 12, 2007 THROUGH CALIFORNIA ENTERPRISE DEVELOPMENT AUTHORITY. SCHEDULE K, PART I, LINE B COLUMN (F) THE 2017 ISSUE REFUNDED $32,500,000 OF SERIES 2012C ISSUE WITH THE ORIGINAL ISSUE DATE OF 11/14/2012. SCHEDULE K, PART IV, COLUMN A CITY OF HOPE COMPLETED THE REBATE COMPUTATION FOR THE 2012 ISSUE IN THE AMOUNT OF $57,928,340 ON SEPTEMBER 3, 2015 WITH NO REBATE LIABILITY DUE. LINDA MALKAS Director MTG SUBSIDY X 500000 395242 false true true 395242 Robert Hickey Spouse of Board Member 176107 Employee Compensation false SCHEDULE L, PART II LOANS TO/FROM INTERESTED PERSONS: LINDA H. MALKAS, PHD, WAS PROVIDED A MORTGAGE ASSISTANCE LOAN AS PART OF HER RECRUITMENT BY THE BECKMAN RESEARCH INSTITUTE. DR. MALKAS MAKES MONTHLY PRINCIPAL AND INTEREST PAYMENTS ON THIS LOAN AND IS CURRENT WITH ALL PAYMENTS. THE LOAN BEARS INTEREST AT 2.42 PERCENT PER ANNUM AND IS SECURED BY REAL PROPERTY IN THE STATE OF CALIFORNIA. THE NOTE IS DUE IN FULL FOR ANY REMAINING OUTSTANDING PRINCIPAL AND INTEREST THE EARLIER OF MAY 9, 2021 OR THE TERMINATION OF DR. MALKAS' EMPLOYMENT. FORM 990, PART III LINE 1 ORGANIZATION'S MISSION - CONTINUATION: BECKMAN RESEARCH INSTITUTE'S MISSION IS TO SUPPORT INNOVATIVE AND CREATIVE RESEARCH AND TO EDUCATE FUTURE SCIENTISTS IN THE BIOLOGICAL SCIENCES. RESEARCH IS OF THE HIGHEST CALIBER AND DIRECTED TO AN UNDERSTANDING OF THE MOLECULES AND PROCESSES OF LIFE, INCLUDING THOSE PROCESSES IMPORTANT TO THE CAUSES, PREVENTION AND CURE OF HUMAN DISEASE. BECKMAN RESEARCH INSTITUTE IS PART OF AN INTEGRATED SYSTEM THAT COMBINES BENCH AND CLINICAL RESEARCH ACTIVITIES DIRECTLY WITH PATIENT CARE, IN BOTH AN IN-PATIENT AND OUT-PATIENT SETTING. THIS INTEGRATED SYSTEM KNOWN AS CITY OF HOPE COLLECTIVELY REFERS TO CITY OF HOPE, CITY OF HOPE NATIONAL MEDICAL CENTER, CITY OF HOPE MEDICAL FOUNDATION, BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, ACCESS CITY OF HOPE, LLC, SOUTHERN CALIFORNIA RADIATION ONCOLOGY, LLC, AND CITY OF HOPE AUXILIARIES. AS AN INNOVATIVE BIOMEDICAL RESEARCH, TREATMENT AND EDUCATIONAL INSTITUTION, WE ARE COMMITTED TO TRANSFORMING THE FUTURE OF HEALTH. EVERY DAY WE TURN SCIENCE INTO PRACTICAL BENEFIT. WE TURN HOPE INTO REALITY. WE ACCOMPLISH THIS THROUGH EXQUISITE CARE, INNOVATIVE RESEARCH, AND VITAL EDUCATION FOCUSED ON ELIMINATING CANCER, DIABETES AND OTHER LIFE-THREATENING DISEASES. CITY OF HOPE IS GUIDED BY A COMPASSIONATE, PATIENT-CENTERED PHILOSOPHY AND SUPPORTED BY A NATIONAL FOUNDATION OF PHILANTHROPY. FORM 990, PART III, LINE 4A PROGRAM SERVICE ACCOMPLISHMENTS - CONTINUATION: RESEARCHERS AT BECKMAN RESEARCH INSTITUTE UNDERTAKE FUNDAMENTAL INVESTIGATIONS IN DIABETES PROGRESSION AND TREATMENT, IMMUNOLOGY AND IMAGING, INTERFERING RNAS AND HIV TREATMENT, TOTAL SYNTHESIS OF COMPLEX AND THERAPEUTIC NATURAL PRODUCTS, MECHANISMS OF DRUG ACTION, NEUROGENESIS, STEM CELL THERAPY, DNA REPAIR AND RADIATION, AND THE IMMUNOBIOLOGY OF VIRAL INFECTION. THEY HAVE ACHIEVED MAJOR ADVANCES IN RECOMBINANT DNA TECHNOLOGY, MONOCLONAL ANTIBODIES, GENE THERAPY, EPIGENETICS, SI-RNA TECHNOLOGY AND CANCER IMMUNOTHERAPEUTICS. A DEPARTMENT IN BECKMAN RESEARCH INSTITUTE IS DEDICATED TO UNDERSTANDING AND DEVELOPING TREATMENTS BASED ON CANCER'S INTERACTION WITH THE IMMUNE SYSTEM. OTHER RESEARCH HAS IDENTIFIED PROTEINS THAT MAY PLAY CRITICAL ROLES IN IMMUNE RESPONSE AND MAY LEAD TO NEW TREATMENT STRATEGIES. ANOTHER MAJOR EMPHASIS FOR THE BECKMAN RESEARCH INSTITUTE SCIENTISTS IS PERSONALIZED RESEARCH AND MEDICINE - ANALYZING A PATIENT'S UNIQUE GENETIC PROFILES TO DEVELOP TAILORED THERAPIES FOR THEIR SPECIFIC DISEASE. ALL OF THIS RESEARCH IS UNIQUELY SUPPORTED BY ONSITE MANUFACTURING FACILITIES THAT CAN TEST AND PRODUCE QUANTITIES OF CELL-BASED, GENE-BASED AND MOLECULAR THERAPIES. THESE FACILITIES FURTHER SERVE AS RESOURCES TO MEDICAL AND SCIENTIFIC RESEARCH CENTERS NATIONWIDE. BECKMAN RESEARCH INSTITUTE SCIENTISTS SERVE AS FACULTY MEMBERS IN CITY OF HOPE'S IRELL & MANELLA GRADUATE SCHOOL OF BIOLOGICAL SCIENCES. THE GRADUATE SCHOOL'S MISSION IS TO TRAIN STUDENTS TO BE OUTSTANDING RESEARCH SCIENTISTS IN CHEMICAL, MOLECULAR AND CELLULAR BIOLOGY. THE SCHOOL IS ACCREDITED BY THE WESTERN ASSOCIATION OF SCHOOLS AND COLLEGES. GRADUATES OF THE PROGRAM, AWARDED A DOCTORATE OF PHILOSOPHY IN BIOLOGICAL SCIENCES, ARE EQUIPPED TO ADDRESS FUNDAMENTAL QUESTIONS IN LIFE SCIENCES AND BIOMEDICINE FOR CAREERS IN ACADEMIA, INDUSTRY AND GOVERNMENT. FORM 990, PART IV, QUESTION 13 AND SCHEDULE E THE BECKMAN RESEARCH INSTITUTE IS ENGAGED IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL AND SCIENTIFIC RESEARCH, AND OPERATES A GRADUATE SCHOOL THAT COMPLIES WITH REV. PROC. 75-50 EVEN THOUGH THE OPERATIONS OF THE GRADUATE SCHOOL REPRESENT LESS THAN 2% OF THE ORGANIZATION'S TOTAL EXPENSES. DUE TO LIMITATIONS IN THE 990 RETURN SOFTWARE APPLICATION, WE ARE UNABLE TO PROVIDE OUR RESPONSES DIRECTLY ON THE SCHEDULE E SCHOOLS QUESTIONNAIRE AND THEREFORE SET FORTH OUR RESPONSES BELOW: 1. DOES THE ORGANIZATION HAVE A RACIALLY NONDISCRIMINATORY POLICY TOWARD STUDENTS BY STATEMENT IN ITS CHARTER, BYLAWS, OTHER GOVERNING INSTRUMENT, OR IN A RESOLUTION OF ITS GOVERNING BODY? "YES" 2. DOES THE ORGANIZATION INCLUDE A STATEMENT OF ITS RACIALLY NONDISCRIMINATORY POLICY TOWARD STUDENTS IN ALL ITS BROCHURES, CATALOGUES, AND OTHER WRITTEN COMMUNICATIONS WITH THE PUBLIC DEALING WITH STUDENT ADMISSIONS, PROGRAMS, AND SCHOLARSHIPS? "YES" 3. HAS THE ORGANIZATION PUBLICIZED ITS RACIALLY NONDISCRIMINATORY POLICY THROUGH NEWSPAPER OR BROADCAST MEDIA DURING THE PERIOD OF SOLICITATION FOR STUDENTS, OR DURING THE REGISTRATION PERIOD IF IT HAS NO SOLICITATION PROGRAM, IN A WAY THAT MAKES THE POLICY KNOWN TO ALL PARTS OF THE GENERAL COMMUNITY IT SERVES? IF YES, PLEASE DESCRIBE, IF NO, PLEASE EXPLAIN. "NO." THE GRADUATE SCHOOL CUSTOMARILY DRAWS A SUBSTANTIAL PERCENTAGE OF ITS STUDENTS FROM LARGE GEOGRAPHIC SECTIONS OF THE UNITED STATES AND INTERNATIONALLY, AND FOLLOWS A RACIALLY NONDISCRIMINATORY POLICY AS DEMONSTRATED BY ITS CURRENT ENROLLMENT OF STUDENTS OF RACIAL MINORITY GROUPS IN MEANINGFUL NUMBERS. ACCORDINGLY, THE GRADUATE SCHOOL SATISFIES THE PUBLICITY REQUIREMENTS OF SECTION 4.03 BY COMPLYING WITH SECTION 4.02 IN THAT IT INCLUDES A STATEMENT OF ITS RACIALLY NONDISCRIMINATORY POLICY AS TO STUDENTS IN ITS CATALOGUES AND ON THE ORGANIZATION'S WEBSITE. 4. DOES THE ORGANIZATION MAINTAIN THE FOLLOWING: 4A. RECORDS INDICATING THE RACIAL COMPOSITION OF THE STUDENT BODY, FACULTY, AND ADMINISTRATIVE STAFF? "YES" 4B. RECORDS DOCUMENTING THAT SCHOLARSHIPS AND OTHER FINANCIAL ASSISTANCE ARE AWARDED ON A RACIALLY NONDISCRIMINATORY BASIS? "YES" 4C. COPIES OF ALL CATALOGUES, BROCHURES, ANNOUNCEMENTS, AND OTHER WRITTEN COMMUNICATIONS TO THE PUBLIC DEALING WITH STUDENT ADMISSIONS, PROGRAMS, AND SCHOLARSHIPS? "YES" 4D. COPIES OF ALL MATERIAL USED BY THE ORGANIZATION OR ON ITS BEHALF TO SOLICIT CONTRIBUTIONS? "YES" 5. DOES THE ORGANIZATION DISCRIMINATE BY RACE IN ANY WAY WITH RESPECT TO: 5A. STUDENT'S RIGHTS OR PRIVILEGES? "NO" 5B. ADMISSIONS POLICIES? "NO" 5C. EMPLOYMENT OF FACULTY OR ADMINISTRATIVE STAFF? "NO" 5D. SCHOLARSHIPS OR OTHER FINANCIAL ASSISTANCE? "NO" 5E. EDUCATIONAL POLICIES? "NO" 5F. USE OF FACILITIES? "NO" 5G. ATHLETIC PROGRAMS? "NO" 5H. OTHER EXTRACURRICULAR ACTIVITIES? "NO" 6A. DOES THE ORGANIZATION RECEIVE ANY FINANCIAL AID OR ASSISTANCE FROM A GOVERNMENTAL AGENCY? "NO" 6B. HAS THE ORGANIZATION'S RIGHT TO SUCH AID EVER BEEN REVOKED OR SUSPENDED? "NO" 7. DOES THE ORGANIZATION CERTIFY THAT IT HAS COMPLIED WITH THE APPLICABLE REQUIREMENTS OF SECTIONS 4.01 THROUGH 4.05 OF REV. PROC. 75-50, 1975-2C.B. 587, COVERING RACIAL NONDISCRIMINATION? "YES" FORM 990, PART V, LINE 2A MOST OF THE CITY OF HOPE OFFICERS AND KEY EMPLOYEES, AS WELL AS A FEW OF ITS HIGHEST COMPENSATED EMPLOYEES, PROVIDE SERVICES TO MORE THAN ONE CITY OF HOPE ENTITY, AND MANY OF THEM PROVIDE SERVICES TO ALL OF THE ENTITIES. FOR A NUMBER OF THESE CONCURRENTLY-EMPLOYED INDIVIDUALS, THE ENTITIES HAVE DESIGNATED THE MEDICAL CENTER AS A "COMMON PAYMASTER" DEFINED IN SECTION 3121(S) OF THE INTERNAL REVENUE CODE. CITY OF HOPE REPORTS THESE CONCURRENT EMPLOYEES' TIME, EFFORT AND COMPENSATION ON THE INFORMATION RETURNS OF THE CITY OF HOPE ENTITIES BASED ON THE ESTIMATES OF THEIR TIME SPENT IN AND FOR EACH ENTITY. AS "COMMON PAYMASTER," THE MEDICAL CENTER ISSUES EACH OF THESE EMPLOYEES A SINGLE, COMBINED PAYCHECK AND ONE FORM W-2. FORM 990, PART VI, SECTION A, LINES 6 AND 7A THE SOLE CORPORATE MEMBER, CITY OF HOPE (95-3435919), ELECTS THE BOARD OF DIRECTORS TO BECKMAN RESEARCH INSTITUTE. FORM 990, PART VI, SECTION A, LINE 7B CERTAIN ACTIONS MAY NOT BE UNDERTAKEN WITHOUT THE PRIOR WRITTEN APPROVAL OF THE SOLE CORPORATE MEMBER, CITY OF HOPE, AS SPECIFIED IN THE GOVERNING DOCUMENTS OF BECKMAN RESEARCH INSTITUTE, INCLUDING: BORROW MONEY IN THE NAME OF BECKMAN RESEARCH INSTITUTE OR UTILIZING PROPERTY OWNED BY BECKMAN RESEARCH INSTITUTE AS SECURITY FOR SUCH LOANS; ASSIGN, TRANSFER, PLEDGE, COMPROMISE OR RELEASE ANY OF THE CLAIMS OR DEBTS TO BECKMAN RESEARCH INSTITUTE EXCEPT ON PAYMENT IN FULL, OR ARBITRATE OR CONSENT TO THE ARBITRATION OF ANY DISPUTE OR CONTROVERSY OF BECKMAN RESEARCH INSTITUTE; MAKE, EXECUTE OR DELIVER ANY ASSIGNMENT FOR THE BENEFIT OF CREDITORS, OR ANY BOND, CONFESSION OF JUDGMENT, CHATTEL MORTGAGE, SECURITY AGREEMENT, DEED, GUARANTY, INDEMNITY BOND, SURETY BOND, OR CONTRACT TO SELL OR BILL OF SALE OF THE PROPERTY OF BECKMAN RESEARCH INSTITUTE; ACQUIRE, PURCHASE, DEVELOP, IMPROVE, SELL, LEASE, OR MORTGAGE ANY CORPORATE REAL ESTATE OR ANY INTEREST THEREIN OR ENTER INTO ANY CONTRACT FOR ANY SUCH PURPOSES; OR MAKE ANY LOAN, INVESTMENT, TRANSFER OR DISPOSITION OF ANY ASSETS OF BECKMAN RESEARCH INSTITUTE OR ENTER INTO ANY CONTRACT OR INCUR ANY LIABILITIES ON BEHALF OF BECKMAN RESEARCH INSTITUTE OTHER THAN FOR FAIR CONSIDERATION AND IN THE ORDINARY COURSE OF BUSINESS RELATING TO ITS NORMAL DAILY OPERATION; OR ESTABLISH CAPITAL AND OPERATING BUDGETS OR ADOPT MATERIAL CHANGES THERETO; OR ANY ACTION THAT COULD REASONABLY BE EXPECTED TO HAVE A MATERIAL ADVERSE EFFECT ON THE 501(C)(3) STATUS OF TAX-EXEMPT BONDS OF CITY OF HOPE AND AFFILIATES. THE FOLLOWING REQUIRE GOVERNING BODY APPROVAL (AS WELL AS THE APPROVAL OF THE SOLE CORPORATE MEMBER): THE ADOPTION OF, OR MATERIAL CHANGE IN, THE MISSION OF BECKMAN RESEARCH INSTITUTE; SALE OR DISPOSITION OF ALL OR SUBSTANTIALLY ALL ASSETS; MERGER AND ITS PRINCIPAL TERMS (AND ANY AMENDMENT TO THOSE TERMS); DISSOLUTION OF THE CORPORATION; ADOPTION OF OPERATING AND CAPITAL BUDGETS; ACQUISITIONS AND CAPITAL EXPENDITURES MEETING A CERTAIN FINANCIAL THRESHOLD; BORROWINGS, GUARANTIES, LOANS, AND BOND ISSUANCE MEETING A CERTAIN FINANCIAL THRESHOLD; CREATION OF A NEW (OR ACQUISITION OF A CONTROLLING INTEREST IN AN EXISTING) CORPORATION, PARTNERSHIP OR LIMITED LIABILITY COMPANY; AND ADOPTION OF OR AMENDMENTS TO INDIVIDUAL CORPORATE INVESTMENT GUIDELINES. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE FORM 990 IS REVIEWED BY THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD OF DIRECTORS OF CITY OF HOPE, WHICH ASSISTS THE BOARD IN FULFILLING ITS RESPONSIBILITIES REGARDING FINANCIAL, ACCOUNTING, AND CORPORATE COMPLIANCE MATTERS OF THE AUXILIARY NETWORK. ADDITIONALLY, THE PREPARATION OF THE FORM 990 IS DONE BY AN EXTERNAL ACCOUNTING FIRM AND IS REVIEWED THOROUGHLY WITH INTERNAL LEADERSHIP AND EXTERNAL PARTICIPANTS, INCLUDING EY, AND RETAINED OUTSIDE TAX COUNSEL. PRIOR TO FILING, THE BECKMAN RESEARCH INSTITUTE FORM 990 IS MADE AVAILABLE TO VOTING MEMBERS OF THE CITY OF HOPE BOARD OF DIRECTORS FOR REVIEW. FORM 990, PART VI, SECTION B, LINE 12C ALL EMPLOYEES OF CITY OF HOPE AND AFFILIATES, BOARD OF DIRECTORS MEMBERS, BOARD COMMITTEE MEMBERS AND RESEARCH TEAM MEMBERS ARE COVERED BY CITY OF HOPE'S APPLICABLE CONFLICT OF INTEREST POLICIES. DETERMINATIONS AS TO WHETHER A CONFLICT OF INTEREST EXISTS AND REVIEW OF CONFLICT DISCLOSURES ARE MADE BY THE CHIEF COMPLIANCE OFFICER, GENERAL COUNSEL AND, AS APPLICABLE, THE CHAIR OF THE BOARD OR THE CONFLICT OF INTEREST AND COMMITMENT COMMITTEE, BASED UPON THE CLASSIFICATION OF PERSON MAKING THE DISCLOSURE. RESTRICTIONS IMPOSED ON PERSONS WITH A CONFLICT VARY, BASED UPON THE FACTS, AND MAY INCLUDE: PROHIBITION FROM PARTICIPATING IN A GOVERNING BODY'S DELIBERATIONS AND VOTING ON A GIVEN TRANSACTION OR SET OF TRANSACTIONS; RECUSAL FROM THE DECISION-MAKING PROCESS RELATING TO BUSINESS TRANSACTIONS (E.G., PURCHASING DECISIONS); PROHIBITION FROM PARTICIPATING AS A PRINCIPAL INVESTIGATOR IN RESEARCH; AND DISCLOSURE OF FINANCIAL INTEREST IN RESEARCH STUDY INFORMED CONSENT FORMS AND PUBLICATIONS. MONITORING TRANSACTIONS FOR CONFLICTS OF INTEREST IS DONE THROUGH ANNUAL REQUIRED DISCLOSURES AND UPDATES BY PERSONS COVERED BY THE ORGANIZATION'S CONFLICT OF INTEREST POLICIES AND A CONCURRENT REVIEW OF SUCH DISCLOSURES AGAINST TRANSACTIONS. CITY OF HOPE POLICY PROVIDES FOR DISCIPLINARY ACTION AGAINST PERSONS COVERED BY THE CONFLICT OF INTEREST POLICIES WHO DO NOT COMPLY WITH POLICY REQUIREMENTS. FORM 990, PART VI, SECTION B, LINES 15A AND 15B THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF CITY OF HOPE'S BOARD OF DIRECTORS (COMMITTEE), PURSUANT TO A DELEGATION OF AUTHORITY FROM THE THE CITY OF HOPE BOARD OF DIRECTORS, IS RESPONSIBLE FOR SETTING THE COMPENSATION OF THE PRESIDENT AND CEO AND CERTAIN OTHER SENIOR EXECUTIVES. THE COMMITTEE ALSO SERVES AS THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE BECKMAN RESEARCH INSTITUTE. THE DIRECTORS ON THIS COMMITTEE ARE INDEPENDENT AND ADHERE TO A STRICT CONFLICT OF INTEREST POLICY. DELIBERATION AND DECISION MAKING ARE SUBSTANTIATED IN THE MINUTES OF THE COMMITTEE'S MEETINGS. THE MINUTES ARE REVIEWED AND APPROVED AT THE NEXT MEETING OF THE COMMITTEE. AS PART OF THE DELIBERATION PROCESS, THE COMMITTEE RECEIVES ADVICE FROM AN INDEPENDENT, THIRD-PARTY COMPENSATION CONSULTANT WITH RESPECT TO EXECUTIVE COMPENSATION, REVIEWS COMPARABLE AND BENCHMARK DATA PRESENTED BY THE CONSULTANT, AND REVIEWS CURRENT COMPENSATION PHILOSOPHY, STRUCTURE, AND ADMINISTRATION OF THE EXECUTIVE CASH COMPENSATION PROGRAMS AT CITY OF HOPE AND AFFILIATES. THE COMMITTEE CARRIES OUT THE BOARD OF DIRECTORS' OVERALL RESPONSIBILITIES RELATING TO EXECUTIVE COMPENSATION. THE EXECUTIVE COMPENSATION PHILOSOPHY IS DESIGNED TO ASSIST IN ATTRACTING AND RETAINING THE CALIBER OF EXECUTIVE LEADERSHIP REQUIRED TO ENABLE CITY OF HOPE TO ACHIEVE THE HIGHEST LEVELS OF COMMUNITY BENEFIT, IMPACT TO CLINICAL CARE, QUALITY RESEARCH AND EFFICIENT PHILANTHROPIC DEVELOPMENT. THE COMMITTEE TARGETS THE 50TH PERCENTILE OF BASE SALARY AND THE 75TH PERCENTILE OF TOTAL CASH COMPENSATION OF THE MARKET IN WHICH CITY OF HOPE COMPETES FOR EXECUTIVES. UNDER THE AIP AND LTI DESCRIBED ABOVE, A SUBSTANTIAL PORTION OF EXECUTIVE COMPENSATION IS LINKED DIRECTLY TO PERFORMANCE GOALS APPROVED IN ADVANCE BY THE COMMITTEE. AS A RESULT, PERFORMANCE COMPENSATION MAY VARY FROM YEAR TO YEAR. GOAL SETTING UNDER THE AIP IS TIED TO ANNUAL PERFORMANCE, INCLUDING THE ATTAINMENT OF SPECIFIC BUSINESS OBJECTIVES FOR STRATEGIC AND FINANCIAL PERFORMANCE AS WELL AS NON-FINANCIAL MEASURES SUCH AS PATIENT SATISFACTION AND QUALITY OF PATIENT CARE. THE LTI IS DESIGNED TO DRIVE LONG-TERM ORGANIZATIONAL PERFORMANCE AND TRANSFORMATION BY ALIGNING EXECUTIVES WITH THE MULTI-YEAR STRATEGIC PLAN AND INCENTIVIZING THEM TO ACHIEVE KEY ORGANIZATIONAL AND STRATEGIC OBJECTIVES AND GOALS. WITH THREE-YEAR VESTING PERIODS, THE LTI ALSO PROVIDES A MEANS FOR RETAINING KEY EXECUTIVE TALENT. THE COMMITTEE CONDUCTS ANNUAL COMPENSATION REVIEWS FOR EXECUTIVES AND CERTAIN KEY EMPLOYEES AND THIS WAS LAST COMPLETED ON DECEMBER 14, 2019. THE COMPENSATION PROGRAMS AND RANGES FOR ALL OFFICERS AND KEY EMPLOYEES LISTED ON FROM 990, PART VII AT THE SVP OR EQUIVALENT LEVEL AND ABOVE ARE REVIEWED BY THIS COMMITTEE. FORM 990, PART VI, SECTION C, LINE 19 BECKMAN RESEARCH INSTITUTE'S ARTICLES OF INCORPORATION ARE AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE. CITY OF HOPE AND AFFILIATES' AUDITED FINANCIAL STATEMENTS ARE AVAILABLE ON THE CITY OF HOPE WEBSITE, AND ITS CONFLICT OF INTEREST POLICIES ARE AVAILABLE BY WRITTEN REQUEST MADE TO THE CONFLICT OF INTEREST MANAGER. BECKMAN RESEARCH INSTITUTE'S BYLAWS ARE NOT MADE AVAILABLE TO THE PUBLIC. FORM 990, PART VII, COLUMN (B) FULL TIME EXEMPT EMPLOYEES GENERALLY WORK IN EXCESS OF 40 HOURS PER WEEK, WHICH HAS BEEN REFLECTED IN PART VII BY AN ESTIMATE OF 60 HOURS PER WEEK. THE MEMBERS OF THE BOARD OF DIRECTORS ARE NOT COMPENSATED FOR SERVING ON THE BOARD. THE HOURS WORKED FOR EACH DIRECTOR IS AN ESTIMATE OF THE TIME SPENT PREPARING FOR AND ATTENDING MEETINGS OF THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS HELD FIVE REGULARLY SCHEDULED MEETINGS DURING FISCAL YEAR 2019. THE AUDIT AND COMPLIANCE COMMITTEE HELD 5 REGULARLY SCHEDULED MEETINGS IN FISCAL YEAR 2019. FORM 990, PART XI, LINE 9 ADJUSTMENT DUE TO CHANGE IN ACCOUNTING GUIDELINES $ (38,847,176) CHANGE IN FAIR VALUE OF INTEREST RATE SWAP AGREEMENT $ (6,479,353) ADJUSTMENT OF ONE TIME OVER THE LIMIT ACCRUAL $ 626,689 --------------- $ (44,699,840) CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953435919 FUNDRAISING CA 501(C)3 7 NA false CITY OF HOPE NATIONAL MEDICAL CENTER 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 HOSPITAL CA 501(C)3 3 CITY OF HOPE true City of Hope Medical Foundation 1500 EAST DUARTE ROAD Duarte CA 91010 274803222 Healthcare CA 501(C)3 3 City of Hope true THE TRANSLATIONAL GENOMICS RESEARCH INST 445 N 5th Street Suite 600 PHOENIX AZ 85004 753065445 RESEARCH AZ 501(C)3 7 CITY OF HOPE true TGEN RESEARCH INSTITUTE FOUNDATION 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 331092191 FUNDRAISING AZ 501(C)3 7 TGEN true SOUTHERN CA RADIATION ONCOLOGY PO BOX 819067 DALLAS TX 75381 MGMT SERVICES CA NA N/A false false true false false false false false false false false true true false true true true false false CITY OF HOPE NATIONAL MEDICAL CENTER l 2946318 FMV CITY OF HOPE NATIONAL MEDICAL CENTER m 47673982 FMV CITY OF HOPE NATIONAL MEDICAL CENTER o 32526564 FMV CITY OF HOPE NATIONAL MEDICAL CENTER p 35999145 FMV CITY OF HOPE NATIONAL MEDICAL CENTER q 13914103 FMV CITY OF HOPE MEDICAL FOUNDATION q 159395 FMV